UPDATE: Credit Suisse Raises PT on St. Jude Medical to $49

Credit Suisse raises its price target to $49 (from $44) on Outperform-rated St. Jude Medical

, following doctor call on Riata. Credit Suisse says, "Yesterday we spoke with doctor who presented on Riata/Riata ST related deaths at ACC. ...This presenter also noted he believes Riata ST likely has a true overall failure rate of ~0.5%/year, which he deemed clinically acceptable. We expect Durata's design improvements to drive an even lower overall failure rate than Riata ST's which should ameliorate Durata-related headline risk as the year progresses." STJ closed at $43.80 a share on Monday.